Evidence Hub

Serum adipokine (apelin) in lean and obese polycystic ovary syndrome patients before and after metformin treatment

M. Hasan, Azza A. Abd El Hameed

Middle East Fertility Society Journal, 2018

59 participants · 12 citations

Abstract

Abstract Background Polycystic ovary syndrome (PCOS) is a common disorder in the childbearing period. Apelin is a regulator of glucose metabolism and is associated with insulin resistance (IR). Metformin is used in PCOS, but its effects on serum apelin in PCOS patients are unknown. Aim To compare serum apelin levels in lean and obese PCOS women and to evaluate the effects of metformin treatment on serum apelin levels, clinical and metabolic parameters, and hormone profile in these patients. Methods A prospective interventional study involving 59 PCOS patients (38 obese and 21 lean) was conducted. Body mass index (BMI), serum apelin, glucose, insulin, FSH, LH and testosterone levels were measured, and HOMA-IR was calculated before and after six months of metformin treatment. Results Significantly higher BMI and serum apelin (P Conclusion Serum apelin levels were higher in obese than lean PCOS patients. Metformin treatment improved insulin sensitivity and decreased serum apelin, LH and testosterone levels in both groups; lean PCOS patients showed better response to metformin treatment.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free